Molecular and Ligand-binding Characterization of the Sigma-receptor in the Jurkat Human T Lymphocyte Cell Line
Overview
Affiliations
The sigma binding site present in the Jurkat human T lymphocyte cell line was investigated. Jurkat cell membranes were found to have a single saturable binding site for [3H]haloperidol, a sigma ligand (dissociation constant, 3.9 +/- 0.3 nM). The binding of [3H]haloperidol was inhibited by several sigma ligands. Northern analysis and reverse transcription-polymerase chain reaction provided evidence for the expression of the recently cloned type 1 sigma-receptor (sigma-R1) in Jurkat cells. The sigma-R1 cDNA cloned from these cells was functional in heterologous expression systems. When expressed in mammalian cells, the cDNA-induced binding was saturable with dissociation constants of 1.9 +/- 0.3 nM for [3H]haloperidol and 12 +/- 2 nM for (+)-pentazocine. The binding of [3H]progesterone, a putative endogenous ligand to sigma-R1, to the Jurkat cell sigma-receptor could be directly demonstrated by using heterologously expressed sigma-R1 cDNA. The binding of [3H]progesterone was saturable, with a dissociation constant of 88 +/- 7 nM. Progesterone and haloperidol interacted with the receptor competitively. Reverse transcription-polymerase chain reaction also produced evidence for the existence of an alternatively spliced sigma-R1 variant in Jurkat cells. This splice variant was found to be nonfunctional in ligand binding assays. This constitutes the first report on the molecular characterization of the sigma-receptor in immune cells.
Xiao Y, Hu X, Xing W, Yan J, Wang R, Li X Front Pharmacol. 2024; 15:1464564.
PMID: 39386030 PMC: 11462627. DOI: 10.3389/fphar.2024.1464564.
Sigma Receptors: Novel Regulators of Iron/Heme Homeostasis and Ferroptosis.
Nguyen N, Jaramillo-Martinez V, Mathew M, Suresh V, Sivaprakasam S, Bhutia Y Int J Mol Sci. 2023; 24(19).
PMID: 37834119 PMC: 10572259. DOI: 10.3390/ijms241914672.
BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting.
Sorbi C, Belluti S, Atene C, Marocchi F, Linciano P, Roy N Int J Mol Sci. 2023; 24(11).
PMID: 37298633 PMC: 10253401. DOI: 10.3390/ijms24119684.
Munguia-Galaviz F, Miranda-Diaz A, Cardenas-Sosa M, Echavarria R Int J Mol Sci. 2023; 24(3).
PMID: 36768323 PMC: 9916216. DOI: 10.3390/ijms24031997.
Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.
Oxombre B, Madouri F, Journe A, Ravez S, Woitrain E, Odou P Int J Mol Sci. 2022; 23(19).
PMID: 36233193 PMC: 9569529. DOI: 10.3390/ijms231911893.